Vertex, jetzt kaufen? Oder noch warten? - 500 Beiträge pro Seite
eröffnet am 23.03.01 19:46:46 von
neuester Beitrag 23.03.01 23:10:32 von
neuester Beitrag 23.03.01 23:10:32 von
Beiträge: 2
ID: 367.212
ID: 367.212
Aufrufe heute: 0
Gesamt: 615
Gesamt: 615
Aktive User: 0
ISIN: US92532F1003 · WKN: 882807 · Symbol: VX1
392,80
EUR
-1,46 %
-5,80 EUR
Letzter Kurs 16:05:53 Tradegate
Neuigkeiten
Vertex Pharmaceuticals Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
06.05.24 · Business Wire (engl.) |
26.04.24 · Business Wire (engl.) |
23.04.24 · PR Newswire (engl.) |
18.04.24 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
0,9998 | +169,42 | |
1,0000 | +33,33 | |
15,370 | +27,34 | |
0,5500 | +22,22 | |
15,348 | +19,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
5,2500 | -19,23 | |
5,2300 | -20,64 | |
1,3500 | -25,82 | |
0,7800 | -29,73 | |
122,80 | -33,44 |
Man lese den letzten Satz:
Biotech: Sell High, Buy Low
Emily Hall, biotech analyst for Morningstar.com
Although during much of 2000 anything remotely connected with
human genome skyrocketed, Hall had difficulty recommending
stocks.
Hall was especially critical of young firms that were several years
away from profitability, such as CRA and HGSI.
Now in 2001, we’re seeing reason returning to sector. Hall sees
recent slide as value correction. But doesn’t mean Biotech is
dead.
Over past 10 years, AMGN and IMNX, have delivered innovative
therapies that have improved patients’ lives and shareholders
accounts.
Hall’s Do’s and Don’ts for Biotech Investing:
Don’t get blinded by science: Companies need a solid business
plan, profitability target, a strong balance sheet and reasonable
valuation. Last year CRA traded as high as $276 a share and the
stock is now trading around $35 a share. Remember science
alone is not enough to invest in a stock. IMGN and MLNM are
other companies that need to be evaluated on more than their
exciting directions in science.
Do pay attention to biotech stocks’ valuations: Biotech stocks
usually trade at a premium to the market but not outlandishly so.
HGSI is an example – it has no product on the market yet but has
a market cap of $5.2 billion. By contrast BGEN has a market cap
of $8.9 billion but had revenues of $962 million.
Don’t performance chase - One of worst ways to buy into any
sector is just because it’s been hot. You should believe in the
sector’s long-term potential and buy when near bottom.
Hall says there is still excess valuation in sector. Advises investors
to be prepared for continued volatility.
Hall’s picks:
DNA, GENZ, AMGN
For very aggressive investors:
VRTX.
Biotech: Sell High, Buy Low
Emily Hall, biotech analyst for Morningstar.com
Although during much of 2000 anything remotely connected with
human genome skyrocketed, Hall had difficulty recommending
stocks.
Hall was especially critical of young firms that were several years
away from profitability, such as CRA and HGSI.
Now in 2001, we’re seeing reason returning to sector. Hall sees
recent slide as value correction. But doesn’t mean Biotech is
dead.
Over past 10 years, AMGN and IMNX, have delivered innovative
therapies that have improved patients’ lives and shareholders
accounts.
Hall’s Do’s and Don’ts for Biotech Investing:
Don’t get blinded by science: Companies need a solid business
plan, profitability target, a strong balance sheet and reasonable
valuation. Last year CRA traded as high as $276 a share and the
stock is now trading around $35 a share. Remember science
alone is not enough to invest in a stock. IMGN and MLNM are
other companies that need to be evaluated on more than their
exciting directions in science.
Do pay attention to biotech stocks’ valuations: Biotech stocks
usually trade at a premium to the market but not outlandishly so.
HGSI is an example – it has no product on the market yet but has
a market cap of $5.2 billion. By contrast BGEN has a market cap
of $8.9 billion but had revenues of $962 million.
Don’t performance chase - One of worst ways to buy into any
sector is just because it’s been hot. You should believe in the
sector’s long-term potential and buy when near bottom.
Hall says there is still excess valuation in sector. Advises investors
to be prepared for continued volatility.
Hall’s picks:
DNA, GENZ, AMGN
For very aggressive investors:
VRTX.
Vorsicht ist noch angesagt.
Ich hatte neulich auch mal gepostet: VERTEX jetzt kaufen.
Es ist noch zu früh. Ich habe mich geirrt. Der Abwärtstrend
ist noch intakt.
Mein Tip: Citibank Call, 767436, Basis 75 $, Laufzeit
17.07.02 (!!!), kaufen bei 8 Cent (Euro), verkaufen 12-14 Cent,
denn VRTX geht zur Zeit wie ein Jojo
Ciao 57er
Die noch heißere Nummer ist: 767437, Basis 90 $
Ich hatte neulich auch mal gepostet: VERTEX jetzt kaufen.
Es ist noch zu früh. Ich habe mich geirrt. Der Abwärtstrend
ist noch intakt.
Mein Tip: Citibank Call, 767436, Basis 75 $, Laufzeit
17.07.02 (!!!), kaufen bei 8 Cent (Euro), verkaufen 12-14 Cent,
denn VRTX geht zur Zeit wie ein Jojo
Ciao 57er
Die noch heißere Nummer ist: 767437, Basis 90 $
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,63 | |
-0,01 | |
+3,08 | |
+0,19 | |
+1,72 | |
-2,52 | |
+3,57 | |
+1,98 | |
-1,36 | |
+0,95 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
162 | ||
157 | ||
118 | ||
55 | ||
54 | ||
52 | ||
49 | ||
45 | ||
39 | ||
37 |
06.05.24 · Business Wire (engl.) · Vertex Pharmaceuticals |
26.04.24 · Business Wire (engl.) · Vertex Pharmaceuticals |
23.04.24 · PR Newswire (engl.) · Vertex Pharmaceuticals |
18.04.24 · Business Wire (engl.) · Vertex Pharmaceuticals |
11.04.24 · dpa-AFX · Amazon |
11.04.24 · dpa-AFX · Amazon |
11.04.24 · dpa-AFX · JPMorgan Chase |
11.04.24 · dpa-AFX · Adobe |
11.04.24 · Sharedeals · Vertex Pharmaceuticals |
10.04.24 · Business Wire (engl.) · Vertex Pharmaceuticals |